

Fig. 1A (Doxorubicin)




Fig. 1A (Daunorubicin)





Fig. 1A (Epirubicin)



Fig. 1A (Idarubicin)











5-FU (10 μ M)
Time (h) 0 24 48 72




Fig. 2B (Oxaliplatin)



Fig. 2E (HCT116)

HCT116					
24h		48h		72h	
CTL	p53	CTL	p53	CTL	p53












Fig. 2E (SW48)

SW48					
24h		48h		72h	
CTL	p53	CTL	p53	CTL	p53






Fig. 3A (HCT116, Etoposide)



Fig. 3A (HCT116, Vosaroxin)



Fig. 3A (SW48, Etoposide)



Fig. 3A (SW48, Vosaroxin)



Buthionine sulfoximine (μM)

0

100










Fig. 3B (HCT116, Sodium arsenite)




Fig. 3B (SW48, Buthionine sulfoximine)









Fig. 3B (SW48, Sodium arsenite)










HCT116

Time (h)	Puromycin				Puromycin + Doxorubicin			
	0	4	8	12	0	4	8	12



	HCT116				
Doxorubicin	-	+	+	+	+
MG132	-	-	+	-	+
Chloroquine	-	-	-	+	+



	SW48				
Doxorubicin	-	+	+	+	+
MG132	-	-	+	-	+
Chloroquine	-	-	-	+	+









Fig. 4D






Fig. 4E





SW48
MLN7243 (1 μM)

Time (h)	0	4	8	12
----------	---	---	---	----










Fig. 4G (HCT116)

Fig. 4G (SW48)





Fig. 4H (HCT116)

Fig. 4H (SW48)











Fig. 4I (Z-VAD-FMK)



Fig. 4I (Z-DEVD-FMK)





	CTL + siNC			YTHDF2 + siNC			YTHDF2 + siMYC		
Doxorubicin (μM)	0		1	0		1	0		1




































SW48

Time (h)	0	8	24
----------	---	---	----












LoVo









Time (h)	0	8	24
----------	---	---	----








	5-FU (10 μ M)			
Time (h)	0	24	48	72







Supplementary Fig. 2E




Supplementary Fig. 2F



Supplementary Fig. 3A




Supplementary Fig. 3B



Supplementary Fig. 3D (HCT116)

Supplementary Fig. 3D (LoVo)




Supplementary Fig. 3E (HCT116)






Supplementary Fig. 3E (LoVo)








CTL		
0 h	12 h	24 h











YTHDF2		
0 h	12 h	24 h










Supplementary Fig. 6D






Supplementary Fig. 6E







HCT116								
input			IgG			FLAG		
CTL	YTHDF2 WT	YTHDF2 MUT	CTL	YTHDF2 WT	YTHDF2 MUT	CTL	YTHDF2 WT	YTHDF2 MUT



SW48								
input			IgG			FLAG		
CTL	YTHDF2 WT	YTHDF2 MUT	CTL	YTHDF2 WT	YTHDF2 MUT	CTL	YTHDF2 WT	YTHDF2 MUT

